Skip to main
NBIX

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences (NBIX) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 55%
Buy 30%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Neurocrine Biosciences Inc is experiencing significant growth driven by strong patient demand and an expanding sales force, which will increase by approximately 30% to enhance the adoption of its lead product, Ingrezza. The company reported impressive quarterly results with Ingrezza sales showing a 10% quarter-over-quarter and 12% year-over-year increase, reaching a record high in prescriptions, alongside Crenessity achieving net product sales of $98 million for Q3. Furthermore, with a robust product pipeline and expectations for its key products to generate substantial revenues in the coming years, Neurocrine Biosciences is positioned for meaningful long-term growth despite potential pricing pressures.

Bears say

Neurocrine Biosciences faces significant competition risks that may hinder the growth of its key product, Ingrezza, particularly in the tardive dyskinesia and Huntington's disease chorea markets, which are already serviced by existing approved therapies. The company’s Crenessity launch has not demonstrated durability, with sales plateauing and falling short of ambitious projections due to competitive pressures and potential compliance issues. Additionally, upcoming pricing pressures from the Inflation Reduction Act could further exacerbate risks to Ingrezza's revenue growth, impacting investor sentiment and the overall stock outlook.

Neurocrine Biosciences (NBIX) has been analyzed by 20 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 30% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurocrine Biosciences (NBIX) Forecast

Analysts have given Neurocrine Biosciences (NBIX) a Buy based on their latest research and market trends.

According to 20 analysts, Neurocrine Biosciences (NBIX) has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurocrine Biosciences (NBIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.